₁Haiying Chen

Summary for 2003 [at-glance overview of Haiying Chen work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author Haiying Chen. According to available data, in 2003 Haiying Chen published at least 1 articles. This work was completed in collaboration with several authors including Wexler, Ruth R and Knabb, Robert M. Many other authors have collaborated with Haiying Chen as well. There is no information about the funding or the grants awarded to support this work.

Analysis of the article abstracts and the titles suggests that Haiying Chen professional interests are focused around "selective orally bioavailable", "orally bioavailable factor" and "bioavailable factor xa". These might also be referred to as "factor xa", "orally bioavailable" or "selective orally". Statistical analysis shows that Haiying Chen's writing is likely to contains terms "factor", "xa", "potent", "bioavailable", "orally" and "selective".

The majority of Haiying Chen articles are affiliated with Bristol-Myers Squibb Company, Pharmaceutical Research Institute, 31 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, USA. Sadly, no email addresses were found for any of the affiliations.

EN FR ES RU

Inaccurate information, needs improvement

make correction leave comment ask question

Images [images we found on the Internet for Haiying Chen]

Do you know Haiying Chen who matches the profile above? Click the photo and let us know!

Alternative names (1) [other authors with names similar to Haiying Chen]

₁₀₂₄Chen, H

Year 2003 Charts [Haiying Chen frequent coauthors and the most common unique vocabulary terms for the selected year]

Historical Performance Charts [graphical overview of Haiying Chen publication and funding history for the range of years]

Haiying Chen Coauthors (11) [all coauthors with the number of joint publications]

1

1

1

1

1

1

1

₃Alexander, Richard S

1

1

1

1

Other [context-specific ads]

Affiliations (1) [condensed summary of the Haiying Chen affiliations, the leading number and the color conveys importance]

₁Bristol-Myers Squibb Company, Pharmaceutical Research Institute, 31 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, USA.

Key Opinion Leader In [Haiying Chen is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

no keywords assigned

Keywords (12) [keywords assigned to Haiying Chen articles by PubMed, the leading number and the color conveys importance]

₁Humans | ₁Pyrazoles | ₁Factor Xa | ₁Administration, Oral | ₁Rabbits | ₁Structure-Activity Relationship | ₁Dogs | ₁Biological Availability | ₁Arteriovenous Shunt, Surgical | ₁Thrombosis | ₁Animals | ₁Crystallography, X-Ray

Haiying Chen Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Haiying Chen might be a good expert witness on these terms]

₈factor | ₈xa | ₅potent | ₄bioavailable | ₄orally | ₄selective | ₃inhibitor | ₃dpc602 | ₃series | ₂selectivity | ₂thrombosis | ₂3-trifluoromethyl-n | ₂4-yl | ₂effective | ₂1'-biphenyl | ₂discovery | ₂phenylpyrazole | ₂serine | ₂inhibition | ₂2-aminomethylphenyl | ₂aminosulfonyl | ₂1h-pyrazole-5-carboxyamide | ₂3-fluoro-2 | ₂inhibitors | ₂compounds | ₂highly | ₁described | ₁shunt | ₁arteriovenous | ₁cascade | ₁led | ₁potential
₈factor xa | ₄orally bioavailable | ₄selective orally | ₄bioavailable factor | ₄potent selective | ₃xa inhibitor | ₂1h-pyrazole-5-carboxyamide dpc602 | ₂aminosulfonyl 1'-biphenyl | ₂dpc602 potent | ₂3-trifluoromethyl-n 3-fluoro-2 | ₂4-yl 1h-pyrazole-5-carboxyamide | ₂1'-biphenyl 4-yl | ₂2-aminomethylphenyl 3-trifluoromethyl-n | ₂discovery 2-aminomethylphenyl | ₂3-fluoro-2 aminosulfonyl | ₂xa inhibitors | ₂highly potent | ₁series ortho | ₁potent compounds | ₁arteriovenous shunt | ₁meta-substituted phenylpyrazoles | ₁analogue highly | ₁pathways coagulation | ₁coagulation cascade | ₁serine proteases | ₁critical juncture | ₁arterial thrombosis | ₁xa potential | ₁juncture intrinsic | ₁treatment venous | ₁cascade paper | ₁series meta-substituted
₄selective orally bioavailable | ₄orally bioavailable factor | ₄bioavailable factor xa | ₄potent selective orally | ₃factor xa inhibitor | ₂3-fluoro-2 aminosulfonyl 1'-biphenyl | ₂aminosulfonyl 1'-biphenyl 4-yl | ₂2-aminomethylphenyl 3-trifluoromethyl-n 3-fluoro-2 | ₂dpc602 potent selective | ₂3-trifluoromethyl-n 3-fluoro-2 aminosulfonyl | ₂factor xa inhibitors | ₂4-yl 1h-pyrazole-5-carboxyamide dpc602 | ₂discovery 2-aminomethylphenyl 3-trifluoromethyl-n | ₂1h-pyrazole-5-carboxyamide dpc602 potent | ₂1'-biphenyl 4-yl 1h-pyrazole-5-carboxyamide | ₂highly potent selective | ₁paper report efforts | ₁potent compounds | ₁xa inhibitor factor | ₁series ortho para-substituted | ₁arteriovenous shunt thrombosis | ₁xa inhibitors optimization | ₁arterial thrombosis recently | ₁phenylpyrazole analogue highly | ₁xa show greater | ₁coagulation cascade paper | ₁xa inhibitors series | ₁show greater 1000-fold | ₁potent | ₁factor xa serine | ₁treatment venous arterial | ₁potent compounds display

Reader's Comments (0) [comments posted by readers of Haiying Chen profile]